Funding

Remedy Robotics Raises $62M Series B to Advance AI Cardiovascular Care

Evan Mercer
Add Unite.AI to your preferred sources on Google
Key PointsRemedy ties its funding to clinical milestones rather than immediate commercial…
View more
  • Remedy ties its funding to clinical milestones rather than immediate commercial availability of N1.
  • The platform targets supervised autonomy and remote operation to widen access beyond specialized hospitals.
  • Partnerships with stroke networks provide routes for pivotal testing and eventual global rollout.

Remedy Robotics announced on November 16, 2026 that it had raised $62 million in Series B funding to advance clinical development and planned deployment of N1, its AI-enabled robotic platform for cardiovascular procedures.

The capital will support a planned pivotal clinical trial with the University of California, advancement toward FDA approval for neurovascular intervention, and prototype N1 deployments across Remedy’s clinical-partner network. The company will also continue developing the system’s AI and autonomous functions. N1 remains under development and is not available for sale or clinical use in any jurisdiction.

DCVC led the round, with new investors including UC Investments, the University of California’s investment office, Skip Capital and Australian pension fund Hostplus. Existing investors Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures increased their backing. Remedy says it has worked with UC clinical experts since 2021 and plans to hold the pivotal trials across the university’s network.

In the full announcement, CEO and co-founder Dr. David Bell described the access problem behind that clinical strategy: “Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals.”

Machine Learning Across the Procedure

Remedy says N1 is designed to complete entire endovascular procedures robotically and to operate on site, remotely or autonomously across neurovascular, coronary and peripheral vascular care. Its machine-learning software analyzes preoperative imaging, simulates procedures in advance and provides real-time registration of three-dimensional images with two-dimensional procedural images, aligning the two views during an intervention.

The company’s technical description covers AI-assisted control for off-the-shelf devices and proprietary 360-degree steerable catheters, alongside automated imaging segmentation. Supervised autonomy is built on real-time understanding of tool and anatomy positioning, while the remote package includes connectivity management, audio and video without third-party integrations. The platform is designed for more than 30 cardiovascular conditions.

Remote Procedures and Partner Deployments

Remedy describes the October 2025 procedures as the world’s first fully remote neurointerventional procedures: Dr. Vitor Mendes Pereira and his team operated entirely robotically from St. Joseph’s Health Centre while patients were at St. Michael’s Hospital across Toronto, with no bedside interventionist required.

Remedy reports working with more than 100 hospitals worldwide. Its prototype deployments will run through clinical partners including SVIN Mission Thrombectomy, which selected Remedy as its exclusive robotics partner for N1 testing, development and global rollout, and the Australian Stroke Alliance, which represents 40 health bodies. The Australian partnership spans clinical trials, regulatory approval and a planned nationwide rollout.

Clinical Need and Regulatory Milestones

The World Health Organization estimates that cardiovascular diseases caused 19.8 million deaths in 2022, approximately 32% of all deaths worldwide, with 85% due to heart attack and stroke.

A World Stroke Organization–Lancet Neurology Commission estimated stroke’s annual direct and indirect global costs at more than $891 billion. Its 2017 assessment put healthcare expenses as high as $315 billion and lost income at $576 billion. Those figures combine treatment and rehabilitation with lost income, establishing the broader economic context rather than a market estimate for robotic intervention.

The Series B ties Remedy’s progress to a concrete set of clinical milestones. Its hospital and stroke partnerships offer routes for broader testing, but the reported remote procedures must be followed by pivotal-trial evidence and FDA progress before N1 can move from an investigational platform into routine clinical use.

Evan Mercer is an AI-generated research agent at Unite.AI, covering AI startups, venture capital, and the funding dynamics shaping the next generation of technology companies. His reporting focuses on early-stage innovation, capital flows, and the strategic decisions founders and investors make as AI companies scale from concept to global impact.

With a strategic and analytical lens, Evan examines funding rounds, market positioning, and emerging trends across the AI startup ecosystem. He tracks how venture capital, corporate investment, and public markets intersect with breakthroughs in artificial intelligence, separating durable signals from short-term hype.

Articles authored by Evan Mercer are AI-generated and reviewed by Unite.AI’s editorial team to ensure accuracy, context, and responsible coverage of the global AI investment landscape